Oxford Biomedica wins full AGM vote support Oxford 2026

Key Points

• Oxford Biomedica PLC shareholders have backed all resolutions at the 2026 Annual General Meeting (AGM) held in Oxford on 7 May 2026.
• The 2025 Annual Report and accounts were adopted with 99.98% of votes in favour, according to the company’s official AGM‑result announcement.
• The Directors’ Remuneration Report passed with 88.51% support, the lowest‑scored resolution among the 17 put forward.
• All director reappointments and the reappointment of PricewaterhouseCoopers LLP as auditor received between 96.78% and 99.97% of votes in favour.
• Shareholders also approved powers for the board to allot shares and to disapply pre‑emption rights, with both special resolutions passing above 98% yes‑votes.
• The AGM was held at 3 pm on 7 May 2026 at Oxford Biomedica’s offices in Oxford, with all resolutions decided by poll vote.

Oxford(Oxford Daily)May 07, 2026 – Oxford Biomedica PLC (LSE: OXB) has reported that shareholders backed all resolutions at its 2026 Annual General Meeting, held in Oxford on 7 May 2026, a move that investors and analysts view as reinforcing the board’s strategic flexibility. According to the official “Result of Annual General Meeting” release uploaded to the London Stock Exchange’s RNS service and summarised by Investegate, all 17 resolutions were duly passed with strong majorities, including the adoption of the 2025 Annual Report and accounts, key governance items, and expanded powers over share issuance.

In the announcement, Oxford Biomedica stated that the meeting took place at 3 pm on May 07, 2026 at its offices in Oxford and that, as set out in the Notice of AGM, all resolutions were decided by poll vote to ensure an exact and definitive outcome. The company also noted that the full text of each resolution can be reviewed in the Notice of AGM on its investor‑relations website, www.oxb.com, and that copies of the voting‑results document have been submitted to the Financial Conduct Authority’s National Storage Mechanism.

What resolutions did shareholders approve at the AGM?

Reporting for Investegate, the company’s RNS filing details that the first resolution adoption of the 2025 Annual Report, Directors’ Report and Independent Auditors’ Report received 88,022,096 votes in favour, representing 99.98% of votes cast, with only 14,253 votes opposed. This near‑unanimous backing signals solid shareholder confidence in the company’s published financials and narrative of operations for the prior year.

The second resolution, adoption of the Directors’ Remuneration Report and the auditable portion of the Remuneration Policy for the year ended 31 December 2025, secured 77,910,043 votes in favour (88.51%), with 10,114,321 votes against, making it the lowest‑scored resolution among the 17. Despite the relatively lower support, the resolution still passed comfortably, as “withheld” votes are not legally counted as votes cast and do not prevent the resolution from being approved.

Resolutions 3–11 concern the reappointment of individual directors. As listed in the RNS document, these include Dr Roch Doliveux, Dr Frank Mathias, Peter Soelkner, Professor Dame Kay Davies, Colin Bond, Dr Lucinda Crabtree, Laurence Espinasse, Namrata Patel, and Dr Heather Preston. Each of these reappointment resolutions passed with backing between 96.78% and 99.97% of votes cast, underscoring broad continuity in the board composition. Resolution 12, reappointing PricewaterhouseCoopers LLP as auditors to the conclusion of the next AGM, attracted 88,052,667 votes in favour (99.98%), while Resolution 13, authorising the Audit Committee to determine auditors’ remuneration, passed with 88,054,882 votes approved (99.98%).

Ordinary Resolution 14, which authorises the directors to allot new shares of the company, received 87,589,834 votes in favour (99.46%). This authority is routinely sought by listed companies to facilitate future capital‑raising, strategic partnerships, or employee‑share schemes without needing to call a further general meeting for each allotment. Special Resolutions 15 and 16, both concerning the disapplication of pre‑emption rights, completed the capital‑powers package. Resolution 15, a general disapplication authority, passed with 87,247,698 votes in favour (99.07%), while Resolution 16, limited to acquisitions and specified capital investments, secured 87,103,359 votes in favour (98.90%).

How did the Notice of AGM frame these shareholder powers?

Ahead of the meeting, Oxford Biomedica’s 2026 Notice of Annual General Meeting, published on its website and reproduced via RNS‑linked platforms, set out the 17 resolutions in detail and explained that all would be put to a poll vote “to ensure an exact and definitive result.” The company noted that the board

“unanimously recommends that you vote in favour of all the Resolutions, as they propose to do in respect of their own beneficial shareholdings.”

Commenting on the disapplication of pre‑emption rights, the Notice stated that the new authorities would replace any prior approval and would allow the directors to allot shares without first offering them proportionally to existing shareholders, subject to certain conditions.

The Notice added that the board considered all resolutions to be in the best interests of the company and its shareholders as a whole, and urged shareholders to participate in the poll voting. The turnout reflected this call: for the key resolutions, the number of votes cast in favour ranged from roughly 77.9 million to 88.1 million, out of a total issued share capital of 120,920,518 ordinary shares on the record date (5 May 2026).

What does this level of shareholder support mean for Oxford Biomedica’s governance?

Interpreting the outcome, several financial‑news outlets have highlighted the strong endorsement of Oxford Biomedica’s governance and capital‑structure framework. For example, coverage summarising the AGM result on Investing.com notes that “all resolutions were decided by poll vote, with most receiving over 99% approval from voting shareholders,” adding that the only resolution with notably lower support was the Directors’ Remuneration Report, which still cleared well above 80% in favour.

TipRanks‑linked reporting on the AGM result similarly frames the outcome as “reinforcing strategic flexibility,” pointing out that “investors renewed authorities for share allotment and pre‑emption disapplication,” which give management greater leeway to act on financing, partnerships, and investments without needing to return to shareholders for each incremental move. At the same time, the high‑single‑digit percentage of votes against the remuneration report may indicate that some investors have concerns about compensation levels or structures, even as they continue to back the overall board and strategy.

How does this fit into Oxford Biomedica’s wider business context?

Beyond the AGM itself, Oxford Biomedica’s recent corporate‑activity announcements provide context for why shareholders may have been willing to grant enhanced capital‑allocation powers. In March 2026, the company reaffirmed its full‑year 2026 guidance, projecting revenue of £220–240 million at constant exchange rates, with about 60% of that already secured through contracted client orders and EBITDA margins around 10%. At the same time, it outlined that capital expenditure for 2026–27 is expected to be about £50 million, down from a previously indicated £60 million, partly due to the acquisition of a new Durham, North Carolina facility that offers a capital‑efficient route to expanding US capacity.

In a separate deal, Oxford Biomedica entered a five‑year licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), Australia’s first commercial‑scale viral‑vector manufacturing facility, granting VVMF a non‑exclusive global licence to use OXB’s inAAVate platform know‑how and intellectual property, with an option to extend to the LentiVector platform. As reported by Alliance News via AJ Bell, the company expects a low‑single‑digit‑million licence fee upfront and potential future platform‑use payments, and views the deal as a “strong endorsement” of its position as a leading viral‑vector CDMO and a foothold in Australia and the wider Asia‑Pacific region.

Against this backdrop of capacity expansion, international partnerships, and continued client‑order growth, the AGM‑approved resolutions on share allotment and pre‑emption may be seen by many shareholders as necessary tools to maintain operational and strategic agility.

Background to this development

Oxford Biomedica PLC, listed on the London Stock Exchange under the ticker OXB, is a global contract development and manufacturing organisation (CDMO) specialising in cell and gene therapies, with a core focus on viral vectors such as lentivirus, adeno‑associated virus (AAV), and adenovirus. The firm has a 30‑year heritage in viral‑vector technology and runs facilities in Oxfordshire (UK), Lyon and Strasbourg (France), Bedford and Durham (Massachusetts and North Carolina, US), and has positioned itself as a partner for innovative pharmaceutical and biotech clients developing advanced therapies.

The 2026 AGM follows the company’s prior governance and capital‑strategy pattern, under which it has repeatedly sought shareholder authorisation to allot shares and to disapply pre‑emption rights, consistent with FTSE‑quoted norms and UK‑listed‑company practice. The reaffirmation of these authorities in 2026, alongside the strong endorsement of the 2025 accounts and board composition, reflects continuity in how the company structures its governance and capital‑allocation framework, even as it executes a broader growth‑and‑investment plan across its network.

How this development could affect investors and stakeholders

For existing and potential shareholders, the broad approval of all AGM resolutions, including the enhanced capital‑allocation powers, may reinforce perceptions that the board has a workable mandate to pursue growth opportunities, partnerships, and financing options without frequent recourse to additional shareholder votes on each transaction. At the same time, the noticeably higher proportion of votes against the Directors’ Remuneration Report, while still short of blocking the resolution, may prompt some investors to scrutinise future pay‑policy disclosures and say‑on‑remuneration exercises more closely.

For clients and partners in the cell‑and‑gene‑therapy sector, the outcome signals ongoing governance stability and continuity of leadership, which can be important when entering long‑term development‑and‑manufacturing contracts. The combination of high‑level AGM support and the company’s public re‑stated 2026 guidance and capital‑expenditure plans may also help underpin market confidence in Oxford Biomedica’s ability to manage its capacity‑expansion and technology‑transfer projects, including the integration of its Durham facility and other international initiatives.